Name: Litfulo Indications: To treat severely patchy hair loss. Active Ingredient: Ritlecitinib Company: Pfizer Labs Approval Date: 6/23/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
Drug Name: Columvi Indications: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy. Active…
Drug Name: Inpefa Indications: To treat heart failure. Active Ingredient: Sotagliflozin Company: Lexicon Pharmaceuticals, Inc Approval Date: 5/26/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf
Drug Name: Paxlovid Indications: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19. Active Ingredient: Nirmatrelvir, Ritonavir Company: Pfizer Labs Approval Date: 5/25/2023 More…
Drug Name: Xacduro Indications: To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Active Ingredient: Sulbactam, Durlobactam Company: Entasis Therapeutics Ltd Approval…
Drug Name: Epkinly Indications: To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy. Active Ingredient:…
Drug Name: Miebo Indications: To treat signs and symptoms of dry eye disease. Active Ingredient: Perfluorhexyloctane Company: Bausch & Lomb Incorporated Approval Date: 5/18/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf
Drug Name: Veozah Indications: To treat moderate to severe hot flashes caused by menopause. Active Ingredient: Fezolinetant Company: Astellas Pharma US, Inc. Approval Date: 5/12/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf
Drug Name: Elfabrio Indications: To treat confirmed Fabry disease. Active Ingredient: Pegunigalsidase alfa-iwxj Company: Chiesi USA, Inc. Approval Date: 5/9/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf
Drug Name: Qalsody Indications: To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation. Active Ingredient: Tofersen Company: Biogen MA Inc. Approval Date: 4/25/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf